Identification of biological markers

PreclinicalBiologic

AAssistance Publique - Hôpitaux de Paris

Identification of biological markers is one of 7 biologic programs targeting Hemophagocytic Syndrome. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hemophagocytic SyndromeActive, not recruiting

Hemophagocytic SyndromePreclinical

Active, not recruiting

Competition

Competitive Landscape

6 competitors in Hemophagocytic Syndrome

#DrugCompanyPhaseTrials

Cytoxan

BBaxter Healthcare Corporation

Rayos

Brukinsa

Tepadina

PEG-Rhg-CSF

CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Preclinical

1 6

Rhg-CSF

CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Preclinical

1 7

Identification of biological markers

AAssistance Publique - Hôpitaux de Paris

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hemophagocytic Syndrome1 trial

Children and Adult Hemophagocytic Syndrome (HLHa)

Completed·AAssistance Publique - Hôpitaux de Paris··NCT02113917·204 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Identification of biological markers. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Identification of biological markers compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Identification of biological markers. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Assistance Publique - Hôpitaux de Paris company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: AAssistance Publique - Hôpitaux de Paris

Identification of biological markers

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hemophagocytic Syndrome1 trial

References

Drug Info

Quick Facts

Related News